Richard F. Pops Chief Executive Officer Alkermes, Inc. Alkermes, Inc., is applying sophisticated drug delivery technologies, product development and manufacturing capabilities to the development of an expanding portfolio of pharmaceutical products. Alkermes has several areas of focus, including: (i) controlled, sustained-release of injectable drugs lasting several days to several weeks, utilizing its ProLease® and Medisorb® technologies and (ii) pulmonary delivery of small molecules and protein and peptide- based drugs utilizing its Advanced Inhalation Research (AIR™) technology. Background Richard Pops has been Chief Executive Officer of Alkermes since February 1991. A native of Los Angeles, California, Richard received a B.A., in Economics from Stanford University in 1983. From 1984 to 1991, he was employed by PaineWebber, Inc., in New York as Vice President of PaineWebber Development Corporation, providing product development financing for the country’s leading biotechnology and high-technology companies. Accomplishments Under Richard's leadership, Alkermes has grown from a privately held company with 25 employees to a publicly traded, leading specialty pharmaceutical company (NASDAQ:ALKS) with more than 400 employees in the United States. The company has raised over $600 million to support the research and development of its product candidates and has consummated important strategic alliances with major pharmaceutical companies, including: Serono, S.A., Eli Lilly and Company, Genentech, Inc., GlaxoSmithKline and Janssen Pharmaceutica, Inc.. The company is recognized as a world leader in the development of injectable, sustained-release formulations of drugs through its ProLease® and Medisorb® technologies. In December 1999, Alkermes and its partner, Genentech, announced the FDA approval of Nutropin Depot™ (rhGH) for the treatment of pediatric growth hormone deficiency, using Alkermes’ ProLease injectable, sustained-release drug delivery system. Alkermes and Janssen Pharmaceutica are developing Risperdal Consta™, an injectable, sustained-release formulation of Janssen’s anti-psychotic drug RISPERDAL®. Risperdal Consta has completed Phase III clinical trials and is pending Regulatory approval. Alkermes has also established a significant presence in the field of pulmonary drug delivery. The pulmonary drug delivery system, known as AIR, offers a unique, proprietary delivery system for optimized drug delivery to the lungs. In the past year, Alkermes has entered into important pulmonary drug delivery collaborations with Eli Lilly and Company and GlaxoSmithKline. Outside Directorships Mr. Pops currently serves on the Board of Directors of: Alkermes, Inc.; Neurocrine Biosciences, Inc.; Reliant Pharmaceuticals, LLC; Genomics Collaborative, Inc.; CombinatoRx, Inc.; Expressive Constructs, Inc.; the Biotechnology Industry Organization (BIO); the Massachusetts Biotechnology Council (MBC); Harvard Medical School Board of Fellows and The Fessenden School Board of Trustees. He also serves as Chair for the Harvard Medical School Advisory Council for Biological Chemistry & Molecular Pharmacology (BCMP) and is an Advisory Board Member of The Cloud Foundation and Polaris Venture Partners.